Human Vaccines & Immunotherapeutics (Jan 2022)

Protecting adults at risk of pneumococcal infection and influenza from exposure to SARS-CoV-2

  • Edwin David George McIntosh,
  • K. Feemster,
  • J. Rello

DOI
https://doi.org/10.1080/21645515.2021.1957647
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 7

Abstract

Read online

There is a paucity of evidence linking pneumococcal infection and influenza with SARS-CoV-2 and COVID-19. There is circumstantial evidence of the possibility of an association between S. pneumoniae and SARS-CoV-2 such as the increased binding of S. pneumoniae to coronavirus-infected human airway epithelium, the frequent use of broad-spectrum antibiotics in the management of COVID-19 which could mask secondary bacterial infection, and the observation that pneumococcal vaccination is associated with decreased SARS-CoV-2 nasopharyngeal swab positivity. We performed a targeted literature review for the year 2020, using search terms S. pneumoniae, influenza, SARS-CoV-2, and found 25 relevant articles of a total of 291. Pneumococcal and influenza vaccinations have the potential to contribute toward efforts aimed at reducing the health burden of SARS-CoV-2, especially by reducing preventable admissions to hospital for pneumonia and the consequent risk of nosocomial SARS-CoV-2 transmission.

Keywords